GB0224014D0 - A protein involved in therapy - Google Patents

A protein involved in therapy

Info

Publication number
GB0224014D0
GB0224014D0 GBGB0224014.1A GB0224014A GB0224014D0 GB 0224014 D0 GB0224014 D0 GB 0224014D0 GB 0224014 A GB0224014 A GB 0224014A GB 0224014 D0 GB0224014 D0 GB 0224014D0
Authority
GB
United Kingdom
Prior art keywords
therapy
protein involved
protein
involved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0224014.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Oxford Glycosciences UK Ltd
Original Assignee
Bayer AG
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Oxford Glycosciences UK Ltd filed Critical Bayer AG
Priority to GBGB0224014.1A priority Critical patent/GB0224014D0/en
Publication of GB0224014D0 publication Critical patent/GB0224014D0/en
Priority to PCT/GB2003/004450 priority patent/WO2004035092A2/en
Priority to AU2003271954A priority patent/AU2003271954A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0224014.1A 2002-10-15 2002-10-15 A protein involved in therapy Ceased GB0224014D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0224014.1A GB0224014D0 (en) 2002-10-15 2002-10-15 A protein involved in therapy
PCT/GB2003/004450 WO2004035092A2 (en) 2002-10-15 2003-10-15 Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases
AU2003271954A AU2003271954A1 (en) 2002-10-15 2003-10-15 Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0224014.1A GB0224014D0 (en) 2002-10-15 2002-10-15 A protein involved in therapy

Publications (1)

Publication Number Publication Date
GB0224014D0 true GB0224014D0 (en) 2002-11-27

Family

ID=9945978

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0224014.1A Ceased GB0224014D0 (en) 2002-10-15 2002-10-15 A protein involved in therapy

Country Status (3)

Country Link
AU (1) AU2003271954A1 (en)
GB (1) GB0224014D0 (en)
WO (1) WO2004035092A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423567T1 (en) * 2001-12-28 2009-03-15 Asubio Pharma Co Ltd COFILIN TO PROMOTE PROLIFERATION AND/OR DIFFERENTIATION OF HEMATOPOETIC STEM CELLS AND/OR HEMATOPOETIC PRONECTOR CELLS
AU2008298888A1 (en) * 2007-09-11 2009-03-19 Cancer Prevention And Cure, Ltd. Identification of proteins in human serum indicative of pathologies of human lung tissues

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
CA2439184A1 (en) * 2000-11-27 2002-05-30 Cytokinetics Inc. Aspergillus fumigatus cofilin
FR2825928B1 (en) * 2001-06-18 2004-04-02 Ecole Norm Superieure Cachan PHARMACEUTICAL COMPOSITION FOR DIAGNOSING, PREVENTING OR TREATING TUMOR PATHOLOGY, COMPRISING AN AGENT MODULATING POLYMERIZATION OF ACTIN

Also Published As

Publication number Publication date
WO2004035092A3 (en) 2004-06-10
WO2004035092A2 (en) 2004-04-29
AU2003271954A8 (en) 2004-05-04
AU2003271954A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
GB0206033D0 (en) Compounds useful in therapy
GB0219776D0 (en) A protein involved in carcinoma
AU2003227861A8 (en) Protein involved in cancer
GB0223272D0 (en) A protein involved in therapy
GB0224014D0 (en) A protein involved in therapy
GB0224013D0 (en) A protein involved in therapy
GB0201808D0 (en) Protein
GB0229902D0 (en) A protein involved in therapy
GB0223958D0 (en) A protein involved in therapy
GB0223292D0 (en) A protein involved in therapy
AU2003278718A8 (en) Stars-a muscle-specification-binding protein
GB0204735D0 (en) Protein
GB0202748D0 (en) Protein
GB0221488D0 (en) A protein involved in carcinoma
GB0221538D0 (en) A protein involved in carcinoma
GB0222483D0 (en) A protein involved in carcinoma
GB0308327D0 (en) A protein involved in cancer
GB0221487D0 (en) A protein involved in pancreatic cancer
GB0229875D0 (en) Protein involved in cancer
GB0230023D0 (en) A new protein
GB0228311D0 (en) A new protein
GB0203040D0 (en) Protein
GB0204476D0 (en) Protein
GB0202668D0 (en) Protein
GB0207009D0 (en) Protein

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)